Personalized Stem Cells, Inc. Submits Investigational New Drug (IND) Application for the Treatment of Osteoarthritis with Stem Cells

POWAY, Calif. (PRWEB) June 18, 2019 Personalized Stem Cells, Inc (“PSCâ€�), a human adipose-derived stem cell company, has submitted an Investigational New Drug (IND) application to the FDA for use of a person’s own adipose-derived stem cells to treat their osteoarthritis. The first clinical…

Source link

Related posts

Chronic Inflammation is of Great Importance in the Progression of Aging


KIF1B{beta} mutations detected in hereditary neuropathy impair IGF1R transport and axon growth


Visual attention is not deployed at the endpoint of averaging saccades


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy